Through chimeric antigen receptor (CAR) technology, NK cells are directionally engineered to enable precise recognition of specific tumor targets. Meanwhile, the in vitro expansion system is optimized to enhance cell activity and persistence. These cells combine target specificity with broad-spectrum anti-tumor properties, allowing them to accurately target tumor cells while reducing off-target risks. They are particularly suitable for the treatment of refractory solid tumors with limited efficacy from conventional therapies, demonstrating stronger anti-tumor durability in clinical applications.